HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ralph Lauren Fragrances

This article was originally published in The Rose Sheet

Executive Summary

Signe Gammeltoft tapped president, Ralph Lauren Fragrances Worldwide, effective July 1, the L'Oréal division announces June 16. Exec replaces L'Oréal U.S. Luxury Products Division President Edgar Huber, who temporarily served as head of the unit following the departure of Andrea Robinson (1"The Rose Sheet" April 4, 2005, In Brief). In her new role, Gammeltoft will "further strengthen" the leadership position of Ralph Lauren fragrances in the U.S., while accelerating the brand's global presence, company notes. She will report directly to L'Oréal USA President and CEO Laurent Attal. In her previous position, Gammeltoft served as president of L'Oréal's Luxury Products Division in the UK, a unit that has achieved "strong success," according to the company...

You may also be interested in...



L’Oréal management

L'Oréal's U.S. Luxury Products Division President Edgar Huber will temporarily assume the role of president of Ralph Lauren Fragrances Worldwide, following the departure of Andrea Robinson, who was named Chief Marketing Officer of the Estee Lauder brand last month, firm says (1"The Rose Sheet" March 28, 2005, In Brief). A permanent successor to Robinson will be announced shortly, L'Oréal adds...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel